Uses
Terodiline, an antispasmodic agent, blocks hERG current with the IC50 of 375 nM.Terodiline has both anticholinergic and calcium antagonist properties, and effectively reduces abnormal bladder contractions caused by detrusor instability.Terodiline can be used for the research of urinary incontinence[1][2].
brand name
Mictrol;Micturin;Mitrol;Miucurin;Terolin.
World Health Organization (WHO)
Terodiline, an anticholinergic and calcium-channel blocking
agent, was first introduced into medicine in the mid 1960s for the treatment of
angina pectoris. In 1986, it was registered for the indication of urinary
incontinence. In 1991, its use in urinary incontinence was reported to be
associated with severe cardiac arrhythmias. This led to a temporary withdrawal in a
few Member States in 1991, followed by a final withdrawal by the manufacturer in
1992.
in vivo
Terodiline (80 mg/kg; S.C.) is equipotent in inhibiting intravesical bladder pressure and carbachol-induced salivary secretion (ID50= 24 and 35 mg/kg, respectively), and in increasing pupil diameter (ED50=59 mg/kg)[1].
| Animal Model: | Fmale or male Hartley guinea pigs (200-600 g)[1] |
| Dosage: | 80 mg/kg |
| Administration: | Administered S.C. |
| Result: | Yielded an ID50 of 24±6 mg/kg. Higher doses were Iethal. |
References
[1] Ruth L Martin, et al. In vitro preclinical cardiac assessment of tolterodine and terodiline: multiple factors predict the clinical experience. J Cardiovasc Pharmacol.2006 Nov;48(5):199-206. DOI:
10.1097/01.fjc.0000246853.15926.d4[2] H D Langtry, et al. Terodiline. A review of its pharmacological properties, and therapeutic use in the treatment of urinary incontinence. Drugs.1990 Nov;40(5):748-61. DOI:
10.2165/00003495-199040050-00008
